0

Anti-obesity Drugs Market by Type, Drug Class, and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 162
  • SKU: IRTNTR70300
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The anti-obesity drugs market is estimated to grow at a CAGR of 12.5% between 2022 and 2027 and the size of the market is forecast to increase by USD 13,693.43 million. The reports include a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 15 vendors along with historical market analysis from 2017 to 2021. Obesity is a major public health concern globally.Obesity has been linked to chronic diseases such as diabetes, hypertension, and cancer, as well as health behavior. Due to the limited efficacy of current drugs, obesity prevalence and incidence are very high worldwide. For the past two decades, obesity has been at its highest level in the US.

This report extensively covers market segmentation by type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs), drug class (peripherally acting drugs and centrally acting drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)).  

What will be the size of the Anti-obesity Drugs Market During the Forecast Period?

Anti-obesity Drugs Market Size

To learn more about this report, Download Report Sample

Who are the Major Anti-obesity Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Key offering - The SCOHIA PHARMA Inc. company offers IMCIVREE treatment which is designed to cure obesity disease as its key offering under the anti-obesity drug segment. Under this segment, the company is involved in offering the specialization in bio venture with great expertise in the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases.

Key Offering -The Alvogen company offers different types of pharmaceutical products including developing, manufacturing, and selling generic, brand, over-the-counter (OTC), and biosimilar products.It also offers Qsymia medicine as a precription which is designed for the treatnent for obesity disease.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Eli Lilly and Co.
  • Empros Pharma AB
  • ERX Pharmaceuticals Inc.
  • Gelesis Inc.
  • GlaxoSmithKline Plc
  • Innovent Biologics Ltd.
  • Novo Nordisk AS
  • Rhythm Pharmaceuticals Inc.
  • VIVUS LLC
  • LG Chem

Anti-obesity Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The growing obese population is notably driving the market growth, although factors such as limited reimbursement for anti-obesity drugs may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Anti-obesity Drugs Market Driver

The use of bariatric surgery limited for morbid obesity is driving the market growth. Morbid obesity is on the rise in the US and may shorten life expectancy. Combinations of diet therapies, exercise, and pharmacotherapy are widely used to treat it, but significant weight loss is often limited and temporary. Morbid obesity is a chronic condition affecting breathing, physical activity, and sleep, and can lead to serious health issues like type 2 diabetes, high blood pressure, back pain, etc. Bariatric surgery offers a cost-effective and successful solution to these problems, and includes techniques such as laparoscopic sleeve gastrectomy, laparoscopic Roux-en-Y gastric bypass, and laparoscopic adjustable gastric banding. It is considered safe and effective, even in patients with multiple sclerosis, and is widely accepted as the most effective treatment for those with extreme obesity. The use of bariatric surgery is therefore increasing.

Key Anti-obesity Drugs Market Trend

An increase in childhood obesity and morbid obesity incidence is the key trend in the market. The prevalence of clinically severe obesity is increasing in the US, although at a slower pace than prior to 2005. Severe and morbid obesity have more serious health consequences than moderate obesity. The prevalence of morbid obesity has been increasing globally in the last 20 years. In the UK, owing to the increased consumption of foods high in fat, salt, or sugar.

The increase in morbid obesity could be linked to increased utilization of healthcare resources in terms of difficulty to transport, transfer, and examine. Routine tasks, including drawing blood, getting X-rays, computed tomography (CT) scans, and emergency department bedside ultrasound, could be more time-consuming in patients with morbid obesity. Other challenges in this patient segment include cardiovascular dysfunction, hypertension, and pulmonary disorders such as respiratory failure and hypoventilation. Thus, increasing incidences of childhood obesity and morbid obesity will increase the demand for anti-obesity drugs, which in turn will propel the growth of the market in focus during the forecast period.

Key Anti-obesity Drugs Market Challenge

Limited reimbursement for anti-obesity drugs is the major challenge impeding the market growth. Obesity is the most prevalent chronic disease worldwide. Although the US is the major market for anti-obesity drugs, the challenges associated with the reimbursement for anti-obesity drugs are more in the US. Bariatric surgery can recover weight-related comorbid diseases and is lifesaving, but the concern about the financial burden remains.

The patient's access to obesity medication through health insurance plan coverage has a barrier to the adoption of obesity medications. In the US payer atmosphere that includes private, government, and employer-based reimbursement schemes and patient movement between these schemes, there is an unwillingness to pay for bariatric surgery and obesity pharmacotherapy due to the perception that obesity is a cosmetic or lifestyle issue, which led payers to limit coverage. Thus, such factors might hamper the growth of the market during the forecast period.

Key Anti-obesity Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Anti-obesity Drugs Market Share by Geography

Global Anti-obesity Drugs Market Customer Landscape

Parent Market Analysis

The reports categorize the global anti-obesity drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

What is the Fastest-Growing Segment in the Anti-obesity Drugs Market?

The market share growth by the class III anti-obesity segment will be significant during the forecast period. Class III anti-obesity drugs is the largest segment of the market and will continue to remain the largest segment during the forecast period. The majority of the drugs offered in the market are targeted at patients categorized under class III obesity. Also, the increase in R and D by manufacturers for new anti-obesity drugs may boost the growth of the global class III market during the forecast period. 

Anti-obesity Drugs Market Size

Get a glance at the market contribution of various segments Request a PDF Sample

The class III anti-obesity drug segment was valued at USD 5,767.88 million in 2017 and continued to grow until 2021. However, its growth momentum is expected to slow down during the forecast period. The main reason for this decline could be the rise in morbid obesity cases. As pharmacotherapy is limited in its ability to decrease BMI and only bariatric surgery can effectively treat morbid obesity with low complications and death rates, the class III anti-obesity drug segment of the market is expected to decrease during the forecast period.

Which are the Key Regions for the Servo Motors And Drives Market?

Anti-obesity Drugs Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 68% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America is the largest geographical segment of the global anti-obesity drugs market and will continue to remain the largest segment during the forecast period. The market is anticipated to grow at moderate growth owing to the rising obese population in North America. Approved drugs such as Qsymia, Saxenda, and BELVIQ generated the highest revenues in North America. The US, Mexico and Canada are the major contributors to the growth of the regional market. 

The US holds the largest market share in the market in North America in 2022. Due to the presence of the highest obese population, the US will continue to lead the global as well as the North American market. Also, due to the availability of FDA-approved anti-obesity drugs and the high prevalence and incidence of adult and childhood obesity, the US is expected to continue to dominate the market during the forecast period. 

The outbreak of COVID-19 affected most countries in North America, especially the US. However, the pandemic has led to an increase in the use of anti-obesity drugs in the region as the severity of COVID-19 in obese people is high. The immunity and healing processes are slower in obese people compared with healthy people. This led to segment growth during COVID-19.

Furthermore, vendors have come up with new business strategies to deal with the increased growth of the market created by the pandemic. Thus, such factors are expected to propel the demand for anti-obesity drugs, which, in turn, will boost the growth of the regional market during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by Type (Class III anti-obesity drugs, Class II anti-obesity drugs, and Class I anti-obesity drugs), Drug Class (Peripherally acting drugs and Centrally acting drugs), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

  • Type Outlook (USD Million, 2017 - 2027)
    • Class III anti-obesity drugs
    • Class II anti-obesity drugs
    • Class I anti-obesity drugs
  • Drug Class Outlook (USD Million, 2017 - 2027)
    • Peripherally acting drugs
    • Centrally acting drugs
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Singapore
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Anti-obesity Drugs Market Scope

Report Coverage

Details

Page number

162

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 12.5%

Market growth 2023-2027

USD 13,693.43 million

Market structure

Fragmented

YoY growth 2022-2023(%)

11.52

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 68%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Alvogen Iceland ehf, Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and LG Chem

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Anti-obesity Drugs Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the anti-obesity drugs market between 2023 and 2027
  • Precise estimation of the anti-obesity drugs market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of anti-obesity drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global anti-obesity drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global anti-obesity drugs market 2017 - 2021 ($ million)
    • 4.2 Type Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.3 Drug class Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Drug class Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Class III anti-obesity drugs - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
    • 6.4 Class II anti-obesity drugs - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
    • 6.5 Class I anti-obesity drugs - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Type
      • Exhibit 46: Market opportunity by Type ($ million)

    7 Market Segmentation by Drug Class

    • 7.1 Market segments
      • Exhibit 47: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Drug Class - Market share 2022-2027 (%)
    • 7.2 Comparison by Drug Class
      • Exhibit 49: Chart on Comparison by Drug Class
      • Exhibit 50: Data Table on Comparison by Drug Class
    • 7.3 Peripherally acting drugs - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
    • 7.4 Centrally acting drugs - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Drug Class
      • Exhibit 59: Market opportunity by Drug Class ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 61: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 62: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 63: Chart on Geographic comparison
      • Exhibit 64: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 101: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 104: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 105: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 106: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 107: Matrix on vendor position and classification
            • 12.3 Alvogen Iceland ehf
              • Exhibit 108: Alvogen Iceland ehf - Overview
              • Exhibit 109: Alvogen Iceland ehf - Product / Service
              • Exhibit 110: Alvogen Iceland ehf - Key offerings
            • 12.4 AstraZeneca
              • Exhibit 111: AstraZeneca - Overview
              • Exhibit 112: AstraZeneca - Product / Service
              • Exhibit 113: AstraZeneca - Key news
              • Exhibit 114: AstraZeneca - Key offerings
            • 12.5 Boehringer Ingelheim International GmbH
              • Exhibit 115: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 116: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 117: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 118: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 119: Boehringer Ingelheim International GmbH - Segment focus
            • 12.6 Cadila Healthcare Ltd.
              • Exhibit 120: Cadila Healthcare Ltd. - Overview
              • Exhibit 121: Cadila Healthcare Ltd. - Business segments
              • Exhibit 122: Cadila Healthcare Ltd. - Key news
              • Exhibit 123: Cadila Healthcare Ltd. - Key offerings
              • Exhibit 124: Cadila Healthcare Ltd. - Segment focus
            • 12.7 Eli Lilly and Co.
              • Exhibit 125: Eli Lilly and Co. - Overview
              • Exhibit 126: Eli Lilly and Co. - Product / Service
              • Exhibit 127: Eli Lilly and Co. - Key offerings
            • 12.8 Empros Pharma AB
              • Exhibit 128: Empros Pharma AB - Overview
              • Exhibit 129: Empros Pharma AB - Product / Service
              • Exhibit 130: Empros Pharma AB - Key offerings
            • 12.9 ERX Pharmaceuticals Inc.
              • Exhibit 131: ERX Pharmaceuticals Inc. - Overview
              • Exhibit 132: ERX Pharmaceuticals Inc. - Product / Service
              • Exhibit 133: ERX Pharmaceuticals Inc. - Key offerings
            • 12.10 Gelesis Inc.
              • Exhibit 134: Gelesis Inc. - Overview
              • Exhibit 135: Gelesis Inc. - Product / Service
              • Exhibit 136: Gelesis Inc. - Key news
              • Exhibit 137: Gelesis Inc. - Key offerings
            • 12.11 GlaxoSmithKline Plc
              • Exhibit 138: GlaxoSmithKline Plc - Overview
              • Exhibit 139: GlaxoSmithKline Plc - Business segments
              • Exhibit 140: GlaxoSmithKline Plc - Key offerings
              • Exhibit 141: GlaxoSmithKline Plc - Segment focus
            • 12.12 Innovent Biologics Ltd.
              • Exhibit 142: Innovent Biologics Ltd. - Overview
              • Exhibit 143: Innovent Biologics Ltd. - Product / Service
              • Exhibit 144: Innovent Biologics Ltd. - Key offerings
            • 12.13 LG Chem
              • Exhibit 145: LG Chem - Overview
              • Exhibit 146: LG Chem - Business segments
              • Exhibit 147: LG Chem - Key news
              • Exhibit 148: LG Chem - Key offerings
              • Exhibit 149: LG Chem - Segment focus
            • 12.14 Novo Nordisk AS
              • Exhibit 150: Novo Nordisk AS - Overview
              • Exhibit 151: Novo Nordisk AS - Business segments
              • Exhibit 152: Novo Nordisk AS - Key offerings
              • Exhibit 153: Novo Nordisk AS - Segment focus
            • 12.15 Rhythm Pharmaceuticals Inc.
              • Exhibit 154: Rhythm Pharmaceuticals Inc. - Overview
              • Exhibit 155: Rhythm Pharmaceuticals Inc. - Product / Service
              • Exhibit 156: Rhythm Pharmaceuticals Inc. - Key offerings
            • 12.16 SCOHIA PHARMA Inc.
              • Exhibit 157: SCOHIA PHARMA Inc. - Overview
              • Exhibit 158: SCOHIA PHARMA Inc. - Product / Service
              • Exhibit 159: SCOHIA PHARMA Inc. - Key news
              • Exhibit 160: SCOHIA PHARMA Inc. - Key offerings
            • 12.17 VIVUS LLC
              • Exhibit 161: VIVUS LLC - Overview
              • Exhibit 162: VIVUS LLC - Product / Service
              • Exhibit 163: VIVUS LLC - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 164: Inclusions checklist
                • Exhibit 165: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 166: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 167: Research methodology
                • Exhibit 168: Validation techniques employed for market sizing
                • Exhibit 169: Information sources
              • 13.5 List of abbreviations
                • Exhibit 170: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Anti-obesity Drugs market growth will increase by $13693.43 million during 2023-2027.
              The anti-obesity drugs market is expected to grow at a CAGR of 12.5% during 2023-2027.
              Technavio has segmented the anti-obesity drugs market by type (Class III anti-obesity drugs, Class II anti-obesity drugs, and Class I anti-obesity drugs) ,drug class (Peripherally acting drugs, Centrally acting drugs, Asia, and ROW) , and geography (North America, Europe, Asia, and Rest of World (ROW)).
              Alvogen Iceland ehf, Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, LG Chem are a few of the key vendors in the anti-obesity drugs market.
              North America will register the highest growth rate of 67.57% among the other regions. Therefore, the anti-obesity drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the anti-obesity drugs market growth are:
              • Growing obese population
              • Research on drugs that target both obesity and type 2 diabetes mellitus
              The anti-obesity drugs market vendors should focus on grabbing business opportunities from the class iii anti-obesity drugs segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>